Shots:

• The P-III TANGO study evaluating the antiviral efficacy and safety of dolutegravir/lamivudine switching to a 2DR vs TAF based regimens in HIV-infected adults who had not experienced prior virologic failure
• The results showed that the 2-drug regimen demonstrated a non-inferior efficacy based on plasma HIV-1 RNA ≥50 c/mL @144wks. & resulted in no virologic failure compared to three drugs regimens in the ITT-E population- non-inferior virologic suppression (85.9% vs 81.7%) respectively- no resistance mutations were observed
• Additionally- no participants treated with dolutegravir/lamivudine met confirmed protocol-defined virologic failure @3yrs.

  | Ref: Businesswire | Image: Viiv Healthcare